journal
MENU ▼
Read by QxMD icon Read
search

Journal of Neuro-oncology

journal
https://www.readbyqxmd.com/read/27900644/elevated-levels-of-p-mnk1-p-eif4e-and-p-p70s6k-proteins-are-associated-with-tumor-recurrence-and-poor-prognosis-in-astrocytomas
#1
Weibing Fan, Weiyuan Wang, Xinfa Mao, Shuzhou Chu, Juan Feng, Desheng Xiao, Jianhua Zhou, Songqing Fan
Malignant astrocytomas are able to invade neighboring and distant areas of the normal brain. Signaling pathway alterations play important role in the development of astrocytomas. Deregulation of eukaryotic translation initiation factor 4E (eIF4E) by MAP kinase-interacting kinases (Mnk) on Ser-209 directly or PI3K/mTOR/S6K pathway indirectly has a critical effect on promoting cellular proliferation, malignant transformation and metastasis. We examined and analyzed the correlation between expression of p-Mnk1, p-eIF4E and p-p70S6K proteins and clinicopathological features in 103 astrocytomas and 54 non-tumorous brain tissues...
November 29, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27900643/first-use-of-patient-reported-outcomes-measurement-information-system-promis-measures-in-adults-with-neurofibromatosis
#2
Mojtaba Talaei-Khoei, Eric Riklin, Vanessa L Merker, Monica R Sheridan, Justin T Jordan, Scott R Plotkin, Ana-Maria Vranceanu
The patient reported outcomes measurement information system (PROMIS) provides clinicians and researchers access to reliable, validated measures of physical, mental, and social well-being. The use of PROMIS can facilitate comparisons among clinical subpopulations and with the U.S. general population. We report on the first study using PROMIS measures in patients with neurofibromatosis (NF). Eighty-six adult patients (mean age = 44; 55% female; 87% white; 50% NF1, 41% NF2 and 9% schwannomatosis) completed a battery of PROMIS computerized adaptive tests (CATs)...
November 29, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27896520/early-perfusion-mri-predicts-survival-outcome-in-patients-with-recurrent-glioblastoma-treated-with-bevacizumab-and-carboplatin
#3
Iwan E Bennett, Kathryn M Field, Christopher M Hovens, Bradford A Moffat, Mark A Rosenthal, Katharine Drummond, Andrew H Kaye, Andrew P Morokoff
Bevacizumab, an anti-angiogenic agent, is FDA-approved for use in patients with recurrent glioblastoma multiforme (rGBM). The radiologic evaluation of tumor response to bevacizumab is complex and there is no validated method of monitoring tumor vascularity during therapy. We evaluated perfusion-weighted MR imaging (PWI) in our cohort of patients enrolled in the CABARET trial, which examined the effectiveness of bevacizumab with or without carboplatin in patients with rGBM. Pre-treatment and early follow-up (4- and 8-week) PWI were used to calculate relative cerebral blood volume (rCBV) histogram statistics of the contrast-enhancing and FLAIR hyperintense tumor volumes...
November 28, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27896519/image-guidance-technology-and-the-surgical-resection-of-spinal-column-tumors
#4
REVIEW
Bhargav Desai, Jonathan Hobbs, Grant Hartung, Guoren Xu, Ziya L Gokaslan, Andreas Linninger, Ankit I Mehta
Precision imaging is paramount to achieving success in surgical resection of many spinal tumors, whether the goal involves guiding a surgical cure for primary tumors or improving neurological decompression for metastatic lesions. Pre-operatively, image visualization is intimately involved with defining a clear target and surgical planning. Intra-operatively, image-guidance technology allows for surgeons to maximize the probability for gross total resection of spinal cord tumors and minimize damage to adjacent structures...
November 28, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27878505/incidence-of-seizure-in-adult-patients-with-intracranial-metastatic-disease
#5
Vivien Chan, Arjun Sahgal, Peter Egeto, Tom Schweizer, Sunit Das
Seizures have considerable impact on a patient's quality of life. While guidelines have been articulated to direct clinicians in their management of patients with IMD who suffer from seizure, there have been few attempts to identify the seizure rate in IMD and to determine which primary cancers may be associated with an increased seizure incidence. To determine the incidence of seizure in patients with IMD. A systematic review on seizure incidence in patients with IMD from the magnetic resonance imaging (MRI) era was performed...
November 22, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27868157/mcm7-expression-is-a-promising-predictor-of-recurrence-in-patients-surgically-resected-for-meningiomas
#6
Theo L Winther, Sverre H Torp
Patients with high risk of recurrence after meningioma resection might benefit from adjuvant radiation therapy and closer clinical follow-up. While the World Health Organization (WHO) classification and the MIB-1 biomarker are applied in the clinical practice to identify these patients, the reliability of these methods is questionable. To improve the prediction of tumor recurrence, this study evaluated and compared the prognostic usefulness of the biomarker MCM7 with the conventional mitotic index and the MIB-1 biomarker...
November 21, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27864707/impact-of-operative-length-on-post-operative-complications-in-meningioma-surgery-a-nsqip-analysis
#7
Aditya V Karhade, Luis Fandino, Saksham Gupta, David J Cote, Julian B Iorgulescu, Marike L Broekman, Linda S Aglio, Ian F Dunn, Timothy R Smith
Many studies have implicated operative length as a predictor of post-operative complications, including venous thromboembolism [deep vein thrombosis (DVT) and pulmonary embolism (PE)]. We analyzed the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database from 2006 to 2014, to evaluate whether length of operation had a statistically significant effect on post-operative complications in patients undergoing surgical resection of meningioma. Patients were included for this study if they had a post-operative diagnosis of meningioma...
November 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27864706/influence-of-insurance-status-and-income-in-anaplastic-astrocytoma-an-analysis-of-4325-patients
#8
Jacob Y Shin, Ja Kyoung Yoon, Aidnag Z Diaz
To determine the impact of insurance status and income for anaplastic astrocytoma (AA). Data were extracted from the National Cancer Data Base. Chi square test, Kaplan-Meier method, and Cox regression models were employed in SPSS 22.0 (Armonk, NY: IBM Corp.) for data analyses. 4325 patients with AA diagnosed from 2004 to 2013 were identified. 2781 (64.3%) had private insurance, 925 (21.4%) Medicare, 396 (9.2%) Medicaid, and 223 (5.2%) were uninsured. Those uninsured were more likely to be Black or Hispanic versus White or Asian (p < 0...
November 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27864705/the-clinical-and-financial-impact-of-a-pediatric-surgical-neuro-oncology-clinical-trial
#9
Eric M Thompson, Sridharan Gururangan, Gerald Grant, Duane Mitchell, John H Sampson
Pediatric surgical trials are rare and the impact of such trials on the institutions in which they are conducted is unknown. The purpose of this study was to analyze the clinical and financial impact of The Re-MATCH trial, a Phase I clinical trial requiring the biopsy or resection of recurrent medulloblastoma or PNET for enrollment. Inpatient financial and clinical volume information was collected during the 3 years of trial enrollment and the years preceding and following it. The primary endpoints were the difference in direct contribution margin (DCM), or net gain, of study and non-study patients and the difference in surgical volume during the study and non-study periods...
November 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27864704/a-clinicopathologic-study-of-extraventricular-neurocytoma
#10
Li Xu, Zhaolian Ouyang, Junmei Wang, Zhaoxia Liu, Jingyi Fang, Jiang Du, Yanjiao He, Guilin Li
In 2007, extraventricular neurocytoma was classified as a separate entity among glioneuronal tumors. However, extraventricular neurocytoma is not fully understood and may be misdiagnosed. Here, we describe the clinical and pathological features, prognoses, and treatments of 13 extraventricular neurocytoma cases, and compare their immunophenotypes with those of oligodendroglioma, diffuse astrocytoma, and ependymoma. Six typical and 7 atypical cases comprised the 13 extraventricular neurocytoma cases. Histological features included oligodendroglioma-like perinuclear halo, neuropil-like matrix, ganglion or ganglioid cells, perivascular pseudorosettes, vessel hyalinization, calcifications, and myxoid degeneration...
November 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27864703/longitudinal-experience-with-who-grade-iii-anaplastic-meningiomas-at-a-single-institution
#11
Suresh K Balasubramanian, Mayur Sharma, Danilo Silva, Vidhya Karivedu, Philipp Schmitt, Glen H Stevens, Gene H Barnett, Richard A Prayson, Paul Elson, John H Suh, Erin S Murphy, Samuel T Chao
To retrospectively analyze and assess the outcomes and prognostic factors in patients with anaplastic meningioma (AM) (WHO Grade III). Clinical data and outcome [overall (OS) and progression-free (PFS) survival] from 18 patients with Grade III meningioma (AM, based on World Health Organization 2016 definition) initially treated between March 2000 and June 2015 were analyzed. Eleven patients (61%) were male, median age at diagnosis was 63 (range 48-86), and 55% (10/18 patients) had good performance status (KPS ≥ 80)...
November 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27858267/correlation-of-higher-levels-of-soluble-tnf-r1-with-a-shorter-survival-independent-of-age-in-recurrent-glioblastoma
#12
Manmeet S Ahluwalia, Stephanie Bou-Anak, Monica E Burgett, Nehaw Sarmey, Divya Khosla, Saurabh Dahiya, Robert J Weil, Eunnyung Bae, Ping Huang, Mary McGraw, Lisa M Grove, Mitchell A Olman, Richard A Prayson, John H Suh, G Yancey Gillespie, Jill Barnholtz-Sloan, Amy S Nowacki, Gene H Barnett, Candece L Gladson
The circulating levels of soluble tumor necrosis factor receptor-1 (sTNF-R1) and sTNF-R2 are altered in numerous diseases, including several types of cancer. Correlations with the risk of progression in some cancers, as well as systemic manifestations of the disease and therapeutic side-effects, have been described. However, there is very little information on the levels of these soluble receptors in glioblastoma (GBM). Here, we report on an exploratory retrospective study of the levels of sTNF-Rs in the vascular circulation of patients with GBM...
November 17, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27858266/reverse-phase-protein-arrays-enable-glioblastoma-molecular-subtyping
#13
Gregor Hutter, Martin Sailer, Tej Deepak Azad, André O von Bueren, Peter Nollau, Stephan Frank, Cristobal Tostado, Durga Sarvepalli, Arkasubhra Ghosh, Marie-Françoise Ritz, Jean-Louis Boulay, Luigi Mariani
In the present study we investigated the phosphorylation status of the 12 most important signaling cascades in glioblastomas. More than 60 tumor and control biopsies from tumor center and periphery (based on neuronavigation) were subjected to selective protein expression analysis using reverse-phase protein arrays (RPPA) incubated with antibodies against posttranslationally modified cancer pathway proteins. The ratio between phosphorylated (or modified) and non-phosphorylated protein was assessed. All samples were histopathologically validated and proteomic profiles correlated with clinical and survival data...
November 17, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27853960/phase-ii-study-of-tivozanib-an-oral-vegfr-inhibitor-in-patients-with-recurrent-glioblastoma
#14
Jayashree Kalpathy-Cramer, Vyshak Chandra, Xiao Da, Yangming Ou, Kyrre E Emblem, Alona Muzikansky, Xuezhu Cai, Linda Douw, John G Evans, Jorg Dietrich, Andrew S Chi, Patrick Y Wen, Stephen Stufflebeam, Bruce Rosen, Dan G Duda, Rakesh K Jain, Tracy T Batchelor, Elizabeth R Gerstner
Targeting tumor angiogenesis is a potential therapeutic strategy for glioblastoma because of its high vascularization. Tivozanib is an oral pan-VEGF receptor tyrosine kinase inhibitor that hits a central pathway in glioblastoma angiogenesis. We conducted a phase II study to test the effectiveness of tivozanib in patients with recurrent glioblastoma. Ten adult patients were enrolled and treated with tivozanib 1.5 mg daily, 3 weeks on/1 week off in 28-day cycles. Brain MRI and blood biomarkers of angiogenesis were performed at baseline, within 24-72 h of treatment initiation, and monthly thereafter...
November 16, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27853959/epidemiology-for-primary-brain-tumors-a-nationwide-population-based-study
#15
Amélie Darlix, Sonia Zouaoui, Valérie Rigau, Faiza Bessaoud, Dominique Figarella-Branger, Hélène Mathieu-Daudé, Brigitte Trétarre, Fabienne Bauchet, Hugues Duffau, Luc Taillandier, Luc Bauchet
Primary central nervous system tumors (PCNST) are rare tumors responsible for high mortality and morbidity. Their epidemiology is poorly known, and clinical data are scarcely analyzed at a national level. In this study, we aimed at providing descriptive epidemiological data and incidence rates for all histological subtypes of PCNST according to the WHO classification. We conducted a nationwide population-based study of all newly diagnosed and histologically confirmed PCNST in France, between 2006 and 2011. A total of 57,816 patients were included: male 46...
November 16, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27853958/beyond-breast-specific-graded-prognostic-assessment-in-patients-with-brain-metastases-from-breast-cancer-treatment-impact-on-outcome
#16
Gaia Griguolo, Maria Vittoria Dieci, Tommaso Giarratano, Carlo Alberto Giorgi, Enrico Orvieto, Cristina Ghiotto, Franco Berti, Alessandro Della Puppa, Cristina Falci, Eleonora Mioranza, Giulia Tasca, Nicola Milite, Federica Miglietta, Renato Scienza, Pierfranco Conte, Valentina Guarneri
Brain metastases are a serious relatively common complication of breast cancer. We evaluated prognostic factors for survival after diagnosis of brain metastases from breast cancer in a contemporary cohort of patients. Patients diagnosed with breast cancer brain metastases at our institution between 1999 and March 2016 were evaluated. Overall survival was defined as time from brain metastasis diagnosis to death or last follow-up. Patients were classified according to the Breast cancer-specific Graded Prognostic Assessment (BS-GPA), based on age, Karnofsky performance score and breast cancer phenotype...
November 16, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27848138/dexamethasone-and-levetiracetam-reduce-hetero-cellular-gap-junctional-coupling-between-f98-glioma-cells-and-glial-cells-in-vitro
#17
Fatme Seval Ismail, Zahra Moinfar, Nora Prochnow, Hannes Dambach, Daniel Hinkerohe, Claus Gert Haase, Eckart Förster, Pedro Michael Faustmann
Gap junctions (GJs) in astrocytes and glioma cells are important channels for cell-to-cell communication that contribute to homo- and heterocellular coupling. According to recent studies, heterocellular gap-junctional communication (H-GJC) between glioma cells and their surrounding environment enhances glioma progression. Therefore, we developed a new in vitro model to examine H-GJC between glioma cells, astrocytes and microglia. Consequently, F98 rat glioma cells were double-labeled with GJ-impermeable (CM-DiI) and GJ-permeable dye (calcein AM) and were seeded on unlabeled astrocyte-microglia co-cultures...
November 16, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27848137/combined-braf-v600e-and-mek-blockade-for-braf-v600e-mutant-gliomas
#18
Jie Zhang, Tsun-Wen Yao, Rintaro Hashizume, Sujatmi Hariono, Krister J Barkovich, Qi-Wen Fan, Michael Prados, C David James, William A Weiss, Theodore Nicolaides
BRAF(V600E) is a common finding in glioma (about 10-60% depending on histopathologic subclassification). BRAF(V600E) monotherapy shows modest preclinical efficacy against BRAF(V600E) gliomas and also induces adverse secondary skin malignancies. Here, we examine the molecular mechanism of intrinsic resistance to BRAF(V600E) inhibition in glioma. Furthermore, we investigate BRAF(V600E)/MEK combination therapy that overcomes intrinsic resistance to BRAF(V600E) inhibitor and also prevents BRAF(V600E) inhibitor induced secondary malignancies...
November 15, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27848136/the-effect-of-idh1-mutation-on-the-structural-connectome-in-malignant-astrocytoma
#19
Shelli R Kesler, Kyle Noll, Daniel P Cahill, Ganesh Rao, Jeffrey S Wefel
Mutation of the IDH1 gene is associated with differences in malignant astrocytoma growth characteristics that impact phenotypic severity, including cognitive impairment. We previously demonstrated greater cognitive impairment in patients with IDH1 wild type tumor compared to those with IDH1 mutant, and therefore we hypothesized that brain network organization would be lower in patients with wild type tumors. Volumetric, T1-weighted MRI scans were obtained retrospectively from 35 patients with IDH1 mutant and 32 patients with wild type malignant astrocytoma (mean age = 45 ± 14 years) and used to extract individual level, gray matter connectomes...
November 15, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27844311/phase-ii-study-of-medi-575-an-anti-platelet-derived-growth-factor-%C3%AE-antibody-in-patients-with-recurrent-glioblastoma
#20
Surasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, Paola Canelos, Rajesh Narwal, Shengyan Hong, Robert Miday, Minal Nade, Kevin Laubscher
MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability...
November 14, 2016: Journal of Neuro-oncology
journal
journal
28661
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"